Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04220190 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04220190 · ClinicalTrials.gov record · last posted 2025-06-18

RAPA-501 Therapy for ALS

StatusRecruiting
PhasePhase 2/3
Started2025-01-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated June 18, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).

Amendment record 21 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 21 times since 2020-01-03; most recent amendment 2025-06-13. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-11-06
Status change Not Yet Recruiting→Recruitingv18
2024-06-14
Status change Recruiting→Not Yet Recruitingv17
2021-01-11
Status change Not Yet Recruiting→Recruitingv7
Trial Details
NCT Number NCT04220190
Lead Sponsor Rapa Therapeutics LLC
Collaborators: Massachusetts General Hospital
Conditions Amyotrophic Lateral Sclerosis
Enrollment 41 participants
Start Date 2025-01-02
Primary Completion 2026-07-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2025-06-18